These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10530409)

  • 1. Leukaemia cell drug resistance and prognostic factors in AML.
    Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
    Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
    Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
    Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
    Nørgaard JM; Langkjer ST; Palshof T; Clausen N; Pedersen B; Hokland P
    Br J Haematol; 1996 Jun; 93(4):888-97. PubMed ID: 8703822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR1 gene expression and drug resistance of AML cells.
    Nørgaard JM; Bukh A; Langkjer ST; Clausen N; Palshof T; Hokland P
    Br J Haematol; 1998 Mar; 100(3):534-40. PubMed ID: 9504636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
    Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
    Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
    Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
    Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.
    Nørgaard JM; Jensen PD; Bendix K; Clausen N; Palshof T
    Leuk Lymphoma; 1999 Jan; 32(3-4):327-37. PubMed ID: 10037030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
    Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine arabinoside in the management of recurrent leukaemia.
    Ganesan TS; Barnett MJ; Amos RJ; Piall EM; Aherne GW; Man A; Lister TA
    Hematol Oncol; 1987; 5(1):65-9. PubMed ID: 3471699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs.
    Nørgaard JM; Langkjer ST; Ellegaard J; Palshof T; Clausen N; Hokland P
    Leuk Res; 1993 Aug; 17(8):689-94. PubMed ID: 7689127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
    Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
    Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
    Seymour JF; Juneja SK; Campbell LJ; Ellims PH; Estey EH; Prince HM
    Leukemia; 1999 Nov; 13(11):1735-40. PubMed ID: 10557046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
    Yang GS; McCulloch EA
    Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.